Clinical Trial Detail

NCT ID NCT04295863
Title Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

Advanced Solid Tumor

Therapies

Nivolumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.